Literature DB >> 22783431

Expression of hypoxia-inducible factor-1α, vascular endothelial growth factor and matrix metalloproteinase-2 in sacral chordomas.

Xiaoxiang Li1, Zhenwei Ji, Yunlei Ma, Xiuchun Qiu, Qingyu Fan, Baoan Ma.   

Abstract

Hypoxia-inducible factor-1α (HIF-1α) has been reported to transactivate the expression of vascular endothelial growth factor (VEGF) and matrix metalloproteinase-2 (MMP-2), which are frequently overexpressed in numerous types of cancer and are known to be significant regulators of angiogenesis. Few studies have investigated the role of these factors in solid tumors, particularly chordomas, which are rare tumors that are thought to originate from notochordal remnants. To clarify whether HIF-1α is involved in angiogenesis in chordoma tissues, we examined the expression of HIF-1α, VEGF and MMP-2 with immunohistochemistry using a tissue microarray containing 35 chordoma samples. The results indicated that HIF-1α, VEGF and MMP-2 are expressed in the majority of chordoma samples. VEGF expression was significantly correlated with HIF-1α and MMP-2 expression, as well as with microvessel density (MVD). However, the prognosis of the chordoma patients was not significantly associated with the expression of these factors, but was associated with MVD. The results therefore showed that there is a correlation between the expression of HIF-1α, VEGF and MMP-2 in chordomas and that the angiogenic process is a potential therapeutic target for chordomas.

Entities:  

Year:  2012        PMID: 22783431      PMCID: PMC3392560          DOI: 10.3892/ol.2012.645

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  28 in total

1.  Chordoma: incidence and survival patterns in the United States, 1973-1995.

Authors:  M L McMaster; A M Goldstein; C M Bromley; N Ishibe; D M Parry
Journal:  Cancer Causes Control       Date:  2001-01       Impact factor: 2.506

2.  Constructing tissue microarrays for research use.

Authors:  Martina Storz Schweizer; Lela Schumacher; Mark A Rubin
Journal:  Curr Protoc Hum Genet       Date:  2004-02

Review 3.  A perspective on cancer cell metastasis.

Authors:  Christine L Chaffer; Robert A Weinberg
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

Review 4.  The hypoxic inducible stress response as a target for cancer drug discovery.

Authors:  Sarah J Welsh; Mei Yee Koh; Garth Powis
Journal:  Semin Oncol       Date:  2006-08       Impact factor: 4.929

5.  Expression of hypoxia-inducible factor-1alpha is associated with tumor vascularization in human colorectal carcinoma.

Authors:  Toshio Kuwai; Yasuhiko Kitadai; Shinji Tanaka; Seiji Onogawa; Norimasa Matsutani; Eijiro Kaio; Masanori Ito; Kazuaki Chayama
Journal:  Int J Cancer       Date:  2003-06-10       Impact factor: 7.396

6.  Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chordomas.

Authors:  Fortios Tzortzidis; Foad Elahi; Donald Wright; Sabareesh K Natarajan; Laligam N Sekhar
Journal:  Neurosurgery       Date:  2006-08       Impact factor: 4.654

7.  Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma.

Authors:  Huachuan Zheng; Hiroyuki Takahashi; Yoshihiro Murai; Zhengguo Cui; Kazuhiro Nomoto; Hideki Niwa; Koichi Tsuneyama; Yasuo Takano
Journal:  Anticancer Res       Date:  2006 Sep-Oct       Impact factor: 2.480

Review 8.  Detection and characterization of tumor hypoxia using pO2 histography.

Authors:  Peter Vaupel; Michael Höckel; Arnulf Mayer
Journal:  Antioxid Redox Signal       Date:  2007-08       Impact factor: 8.401

Review 9.  Evaluation of HIF-1 inhibitors as anticancer agents.

Authors:  Gregg L Semenza
Journal:  Drug Discov Today       Date:  2007-09-18       Impact factor: 7.851

Review 10.  Chordoma: the nonsarcoma primary bone tumor.

Authors:  Rashmi Chugh; Hussein Tawbi; David R Lucas; J Sybil Biermann; Scott M Schuetze; Laurence H Baker
Journal:  Oncologist       Date:  2007-11
View more
  10 in total

1.  Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence.

Authors:  Kai Zhang; Hao Chen; Bin Zhang; Jiajia Sun; Jian Lu; Kangwu Chen; Huilin Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

2.  Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma.

Authors:  Shuyu Hao; Hua Song; Wei Zhang; Ashlee Seldomridge; Jinkyu Jung; Amber J Giles; Marsha-Kay Hutchinson; Xiaoyu Cao; Nicole Colwell; Adrian Lita; Mioara Larion; Dragan Maric; Mones Abu-Asab; Martha Quezado; Tamalee Kramp; Kevin Camphausen; Zhengping Zhuang; Mark R Gilbert; Deric M Park
Journal:  Neuro Oncol       Date:  2018-05-18       Impact factor: 12.300

3.  Advancement of PI3 Kinase Inhibitor Combination Therapies for PI3K-Aberrant Chordoma.

Authors:  Molly E Heft Neal; Nicole L Michmerhuizen; Kevin J Kovatch; John Henry J Owen; Jingyi Zhai; Hui Jiang; Erin L McKean; Mark E P Prince; J Chad Brenner
Journal:  J Neurol Surg B Skull Base       Date:  2020-10-12

4.  Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO).

Authors:  E Bompas; A Le Cesne; E Tresch-Bruneel; L Lebellec; V Laurence; O Collard; E Saada-Bouzid; N Isambert; J Y Blay; E Y Amela; S Salas; C Chevreau; F Bertucci; A Italiano; S Clisant; N Penel
Journal:  Ann Oncol       Date:  2015-07-22       Impact factor: 32.976

5.  Investigating microenvironmental regulation of human chordoma cell behaviour.

Authors:  Priya Patel; Courtney Brooks; Ayesh Seneviratne; David A Hess; Cheryle A Séguin
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

6.  Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity.

Authors:  Hadley E Sheppard; Alessandra Dall'Agnese; Woojun D Park; M Hamza Shamim; Julien Dubrulle; Hannah L Johnson; Fabio Stossi; Patricia Cogswell; Josh Sommer; Joan Levy; Tanaz Sharifnia; Mathias J Wawer; Behnam Nabet; Nathanael S Gray; Paul A Clemons; Stuart L Schreiber; Paul Workman; Richard A Young; Charles Y Lin
Journal:  Cell Rep Med       Date:  2021-01-19

7.  Mutation Analysis of Nine Chordoma Specimens by Targeted Next-Generation Cancer Panel Sequencing.

Authors:  Carina Fischer; Susanne Scheipl; Agnes Zopf; Norbert Niklas; Alexander Deutsch; Mette Jorgensen; Birgit Lohberger; Elke Verena Froehlich; Andreas Leithner; Christian Gabriel; Bernadette Liegl-Atzwanger; Beate Rinner
Journal:  J Cancer       Date:  2015-08-20       Impact factor: 4.207

8.  Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series.

Authors:  Astrid Lipplaa; Sander Dijkstra; Hans Gelderblom
Journal:  Clin Sarcoma Res       Date:  2016-11-01

Review 9.  Microenvironmental Targets in Sarcoma.

Authors:  Monika Ehnman; Olle Larsson
Journal:  Front Oncol       Date:  2015-11-04       Impact factor: 6.244

10.  Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).

Authors:  Loic Lebellec; François Bertucci; Emmanuelle Tresch-Bruneel; Emmanuelle Bompas; Yves Toiron; Luc Camoin; Olivier Mir; Valerie Laurence; Stephanie Clisant; Emilie Decoupigny; Jean-Yves Blay; Anthony Goncalves; Nicolas Penel
Journal:  Oncotarget       Date:  2016-11-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.